Company intelligence / Profile preview
Amalfi Bio
South San Francisco, California, United Statesamalfibio.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Amalfi Bio is a pre-clinical stage biotechnology company dedicated to developing novel therapies for rare and severe genetic diseases. The company utilizes a proprietary platform focused on chaperone-mediated protein folding to address the root causes of protein misfolding and proteotoxicity. By modulating the cellular machinery responsible for protein quality control, Amalfi Bio aims to restore functional protein levels and improve patient outcomes. Headquartered in South San Francisco, the company was founded by industry veterans and is backed by leading life sciences investors like Third Rock Ventures.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small moleculePeptidomimetic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Amalfi Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amalfi Bio.